Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.39 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.39 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.39 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13042911 | 0.93 | CACNA2D1 (0.35) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL13042868 | 0.85 | CACNA2D1 (0.33) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL787007 | 0.83 | SMN1; SMN2 (0.33) | — | |
| SCHEMBL13042894 | 0.81 | CACNA2D1 (0.31) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL1701907 | 0.78 | — | — | |
| SCHEMBL14586568 | 0.78 | NPC1 (0.30) | — | |
| SCHEMBL786860 | 0.78 | NPC1 (0.30) | — | |
| SCHEMBL14586576 | 0.75 | CACNA2D1 (0.32) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL13042904 | 0.74 | MMP12 (0.34) | — | |
| SCHEMBL13042902 | 0.74 | CACNA2D1 (0.33) | CACNA2D1CACNB3CACNA1CPGRADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150166342-A1 | Functionalized Matrices for Dispersion of Nanostructures | NANOSYS, INC. (US) | 2015-06-18 | — | — | US | disclosed |
| US-8916064-B2 | Functionalized matrices for dispersion of nanostructures | NANOSYS, INC. (US) | 2014-12-23 | — | — | US | disclosed |
| US-20140151600-A1 | Functionalized Matrices for Dispersion of Nanostructures | NANOSYS, INC. (US) | 2014-06-05 | — | — | US | disclosed |
| US-20130043433-A1 | Functionalized Matrixes for Dispersion of Nanostructures | NANOSYS, INC. (US) | 2013-02-21 | — | — | US | disclosed |
| US-20120068118-A1 | NANOCRYSTAL DOPED MATRIXES | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120068118-A1 | NANOCRYSTAL DOPED MATRIXES | STRA6, EPHA6, PIR | CACNA2D1 1655/4885CACNB3 2743/4885CACNA1C 2874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.